[Significance of biomarkers for metabolic syndrome during weight reduction].
BACKGROUND
Obesity is a risk factor for type 2 diabetes, hypertension, dyslipidemia and cardiovascular disease. We aimed to analyse the changes of parameters of the metabolic syndrome and to investigate which markers are useful in the prediction of a successful weight loss. Preliminary data of an ongoing study are presented.


METHODS
18 obese individuals (15 female, 3 male, mean age 50.9 years, mean BMI 36.1) finished a 12 month weight loss program. This weight loss program was based on a hypocaloric diet (50 % carbohydrates, 30 % fat, 20 % protein) and at least 60 min physical activity per week. At baseline, 6 months and 12 months physical examination, indirect calorimetry, bioimpedance analysis were performed and blood was taken for routine laboratory. An oral glucose tolerance test and an euglycemic hyperinsulinemic clamp (n = 13) were carried out at baseline and after 6 months.


RESULTS
There was a decrease of the BMI (+/- SEM) from 36.1 +/- 1.3 to 33.4 +/- 1.2 after 6 months and 32.8 +/- 1.3 after 12 months. Waist circumference (-8.8 cm), fasting blood glucose (98.0 to 91.2 and 92.5 mg/dl) and HDL cholesterol (47.2 to 64.6 mg/dl after 12 months) improved significantly. Other parameters of the metabolic syndrome (blood pressure, lipids, insulin resistance) and adiponectin improved slightly, but changes failed to be significant. In a linear regression analysis age, insulin resistance (M-value) and adiponectin at baseline were significant and independent predictors of a successful weight loss.


CONCLUSIONS
In conclusion, most parameters of the metabolic syndrome improved after successful weight reduction, although changes of most parameters were modest and did not reach statistical significance.
Rochlitz
H
H
Deutsches Institut für Ernährungsforschung Potsdam, Nuthetal und Abteilung für Endokrinologie, Diabetes und Ernährungsmedizin, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Deutschland. helmut.rochlitz@charite.de
Akpulat
S
S
Bobbert
T
T
Mai
K
K
Möhlig
M
M
Osterhoff
M
M
Weickert
M O
MO
Pfeiffer
A F
AF
Spranger
J
J
D052242:Adiponectin; D000328:Adult; D000367:Age Factors; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D004038:Diet, Reducing; D015444:Exercise; D005215:Fasting; D005260:Female; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis; D016014:Linear Models; D008297:Male; D024821:Metabolic Syndrome / Q000503:physiopathology*; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000503:physiopathology / Q000628:therapy*; D049629:Waist-Hip Ratio; D015431:Weight Loss / Q000502:physiology*
D052242:Adiponectin; D015415:Biomarkers; D001786:Blood Glucose; D008076:Cholesterol, HDL; D036341:Intercellular Signaling Peptides and Proteins